Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion type Assertion NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_head.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion description "[We performed screening of beta-galactosidase-deficient fibroblasts for possible chemical chaperone therapy using N-octyl-4-epi-beta-valienamine (NOEV) in patients with GM1-gangliosidosis and Morquio B disease (beta-galactosidosis).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_provenance.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion evidence source_evidence_literature NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_provenance.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion SIO_000772 16617000 NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_provenance.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion wasDerivedFrom befree-2016 NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_provenance.
- NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_assertion wasGeneratedBy ECO_0000203 NP545081.RAdXNoHEY7gLaGuQ95Pxh8qC8TnReDoUo_DP1D3SozPQY130_provenance.